Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 278-770-4 | CAS number: 77804-81-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 25 MAR 1981 to 2 APR 1981
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Basic data given: comparable to guidelines
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 981
- Report date:
- 1981
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- GLP compliance:
- yes
- Type of assay:
- micronucleus assay
Test material
- Reference substance name:
- 2-[(4-chloro-2-nitrophenyl)azo]-N-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-3-oxobutyramide
- EC Number:
- 235-462-4
- EC Name:
- 2-[(4-chloro-2-nitrophenyl)azo]-N-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-3-oxobutyramide
- Cas Number:
- 12236-62-3
- Molecular formula:
- C17H13ClN6O5
- IUPAC Name:
- 2-[(4-chloro-2-nitrophenyl)diazenyl]-3-oxo-N-(2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)butanamide
- Test material form:
- solid: bulk
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- NMRI
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Hoechst AG, company breeding colony
- Age at study initiation: 7 to 12 weeks
- Weight at study initiation: males mean: 33 g; females mean: 26 g
- Housing: grouped (5 animals per cage) in macrolon cages (type 3) in fully airconditioned rooms
- Diet: rats/mice diet Altromin1324 (Altromin GmbH, Lage/Lippe, Germany), ad libitum
- Water: tap water, ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22+/-2
- Humidity (%): 55+/-10
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle(s)/solvent(s) used: 2% starch mucilage
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
Test compound:
Preparation of compounds dilution was done freshly each day.
6250 mg of test item were weight in a beaker, mixed with 2% starch mucilage, transferred into a 25 mL flask and topped up to the calibration mark. A solution was formed by stirring for 5 minutes on a magnetic stirrer.
Positive control:
For Endoxan(R) (= Cyclophosphamide) stock solution, 5 ml of distilled water were added to 100 mg Endoxan(R) in an injection phial and shaken to form a clear solution. The solutions for administration were prepared from this stock solution. For this purpose, 2 ml of the 2% stock solution were mixed with 6 ml distilled water. - Duration of treatment / exposure:
- 30 hours in total (1st application, lack phase of 24 hours, 2nd application, after 6 hours termination of test)
- Frequency of treatment:
- twice
- Post exposure period:
- 6 hours
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 50, 500, 5000 mg/kg bw
Basis:
actual ingested
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- cyclophosphamide
- Route of administration: oral, gavage
- Doses / concentrations: 100 mg/kg bw
Examinations
- Tissues and cell types examined:
- polychromatic erythrocytes derived from the bone marrow
- Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION:
According to a preliminary study, the maximal applicable dose of the test item is 5000 mg per kg bodyweight, which was administered twice.
DETAILS OF SLIDE PREPARATION:
At the indicated time a suspension of the bone marrow of both femora was formed. The mixture was then centrifuged for 5 minutes at about 1000 rpm and almost all the supernatant discarded. One drop of the thoroughly mixed sediment was smeared an a cleaned slide and air-dried for about 24 hours.
Staining procedure
- 3 minutes in May-Grünwalds solution
- 2 minutes in May-Grünwalds solution diluted 1:1 with distilled water
- brief rinsing twice in distilled water
- 10 minutes staining in 1 part Giemsa solution to 6 parts distilled water
- rinsing in distilled water
- drying with filter paper
- cleaning the backside of the slide with methanol
- 5 minutes in xylene
- coating with Entellan - Evaluation criteria:
- 2000 polychromatic erythrocytes were counted for each animal. The number of cells with micronuclei was recorded, not the number of individual micronuclei. As a control measure 1000 mature erythrocytes were also counted and examined for micronuclei. In addition, the ratio of polychromatic to normochromatic erythrocytes was determined. All bone marrow smears for evaluation are coded to ensure that the group to which they belonged remains unknown to the investigator.
- Statistics:
- The number of polychromatic erythrocytes with micronuclei occurring in the 2000 polychromatic erythrocytes counted, and the number of normocytes with micronuclei occurring in the 1000 normocytes counted, were evaluated statistically. Increases in dose groups compared to the simultaneous control group were determined using binominal distribution. Differences in dose groups compared to the simultaneous control group were checked using the method of Nemenyi (separately for both sexes).
The statistical evaluations were performed using a in-house computer program. All statistical results are based on a 95 % level of significance.
Results and discussion
Test results
- Key result
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Vehicle controls validity:
- valid
- Negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- Faeces was stained orange in all animals of dose group 500 and 5000 mg/kg bw.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): negative
The results indicate that, under the conditions of the present study, the test item is not mutagenic in the micronucleus test. - Executive summary:
The test item was tested in a micronucleus test conducted similar to OECD guideline 474. The test compound was administered orally by gavage to male and female mice. The following doses were tested: 0, 50, 500 and 5000 mg per kg bodyweight.
The animals were treated twice within 24 h with the test compound and according to the test procedure the animals were killed 6 hours after the second administration of the test compound.
The incidence of micronucleated polychromatic erythrocytes of the animals treated with the test item was within the normal range of the negative control. The number of normochromatic erythrocytes containing micronuclei was not increased compared to the control animals.The ratio of polychromatic/normochromatic erythrocytes in both male and female animals remained unaffected by the treatment.
The positive control (Cyclophosphamide = EndoxanR) yielded positive results and therefore indicating the sensitivity of the system.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.